Non-Current Assets
Operating Lease Right-of-Use Assets in Other Assets
Alnylam Pharmaceuticals Operating Lease Right-of-Use Assets in Other Assets decreased by 2.9% to $189.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 4.0%, from $197.23M to $189.30M. Over 5 years (FY 2020 to FY 2025), Operating Lease Right-of-Use Assets in Other Assets shows a downward trend with a -4.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2025
Last reportedQ1 2026
Metric ID:
operating_lease_rou_assets_in_otherHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $238.09M | $235.85M | $231.68M | $228.77M | $223.92M | $218.80M | $215.14M | $215.05M | $208.80M | $203.49M | $199.73M | $195.47M | $198.30M | $196.41M | $191.15M | $197.23M | $192.40M | $191.39M | $194.92M | $189.30M |
| QoQ Change | — | -0.9% | -1.8% | -1.3% | -2.1% | -2.3% | -1.7% | -0.0% | -2.9% | -2.5% | -1.8% | -2.1% | +1.5% | -1.0% | -2.7% | +3.2% | -2.4% | -0.5% | +1.8% | -2.9% |
| YoY Change | — | — | — | — | -6.0% | -7.2% | -7.1% | -6.0% | -6.8% | -7.0% | -7.2% | -9.1% | -5.0% | -3.5% | -4.3% | +0.9% | -3.0% | -2.6% | +2.0% | -4.0% |
Range$189.30M – $238.09M
CAGR-4.7%
Avg YoY Growth-4.7%
Median YoY Growth-5.5%
Operating Lease Right-of-Use Assets in Other Assets at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's operating lease right-of-use assets in other assets?
- Alnylam Pharmaceuticals (ALNY) reported operating lease right-of-use assets in other assets of $189.30M in Q1 2026.
- How has Alnylam Pharmaceuticals's operating lease right-of-use assets in other assets changed year-over-year?
- Alnylam Pharmaceuticals's operating lease right-of-use assets in other assets decreased by 4.0% year-over-year, from $197.23M to $189.30M.
- What is the long-term trend for Alnylam Pharmaceuticals's operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's operating lease right-of-use assets in other assets has grown at a -4.2% compound annual growth rate (CAGR), from $241.49M to $194.92M.